Reprogramming energy metabolism is a hallmark of malignant tumors, including glioblastoma (GBM). Aerobic glycolysis is often utilized by tumor cells to maintain survival and proliferation. However, the underlying mechanisms of aerobic glycolysis in GBM remain elusive. Herein, we demonstrated that large intergenic non-coding RNA-RoR (LincRNA-RoR) functioned as a critical suppressor to inhibit the aerobic glycolysis and viability of GBM cells. We found that LincRNA-RoR was markedly reduced in GBM tissues compared with adjacent non-tumor tissues from 10 cases of GBM patients. Consistently, LincRNA-RoR expression in GBM cells was significantly lower than that in normal glial cells. The aerobic glycolysis of GBM cells, as determined by the measurement of glucose uptake and lactate production, was impaired by LincRNA-RoR overexpression. Mechanistically, LincRNA-RoR inhibited the expression of Rictor, the key component of mTORC2 (mammalian target of rapamycin complex 2), to suppress the activity of Akt pathway and impair the expression of glycolytic effectors, including Glut1, HK2, PKM2 and LDHA. Finally, enforced expression of LincRNA-RoR reduced the proliferation of GBM cells in vitro, restrained tumor growth in vivo, and repressed the expression of glycolytic molecules in GBM xenografts. Collectively, our results underscore LincRNA-RoR as a new suppressor of GBM aerobic glycolysis with therapeutic potential.
Introduction
Cancer cells prefer to obtain energy from aerobic glycolysis [1] [2] [3] , which produces more lactate but less ATP, a phenomenon called "Warburg effect". The conversion from glucose to lactate in the presence of oxygen facilitates proliferation, migration and invasion of cancer cells [2, 4, 5] . Consequently, the amount of lactate produced in the microenvironment is closely correlated with tumor malignancy, and lactate promotes the survival of tumor cells by decreasing the oxidative stress via consuming the reactive oxygen species [4, 6, 7] .
Glioblastoma (GBM) is the most common and aggressive primary human brain tumor with high mortality [8] . The survival of GBM patients has not been significantly prolonged despite of significant progress in therapeutic strategies, such as surgical practices, new radiotherapy techniques and molecule-targeted therapies [9, 10] . Although GBM is highly-vascularized [11] , bevacizumab, an antibody targeting vascular endothelial growth factor (VEGF), failed to improve the survival of GBM patients partially due to the induction of metabolic switch toward glycolysis in GBM cells [12] . In addition, several key glycolytic effectors, such as glucose transporter 1 (Glut1), hexokinase 2 (HK2), pyruvate kinase 2 (PKM2) and lactate dehydrogenase A
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International Publisher (LDHA), are aberrantly expressed in glioma cells and play vital roles in tumorigenesis [5, 13] . Thus, clarification of the regulatory molecules of glycolysis is important for understanding the mechanism of GBM progression and exploring new targeted therapeutic strategies for GBM.
The long non-coding RNAs are RNA molecules over 200 nucleotides in length [14] , and involved in multiple physiological and pathological processes, including carcinogenesis [15, 16] . Large intergenic non-coding RNA-RoR (LincRNA-RoR) was firstly identified and characterized in induced pluripotent stem cells and human embryonic stem cell by microarray screening and functional validation [17, 18] . Altered expression of LincRNA-RoR has also been shown to mediate various cellular processes in cancer cells, including proliferation, metastasis, invasion and apoptosis [19] . However, the regulation of glucose metabolism by LincRNA-RoR in cancer cells has not been explored.
In this study, we detect the expression of LincRNA-RoR in GBM tissues and the matched non-tumor tissues, investigate the effect and corresponding mechanism of LincRNA-RoR on aerobic glycolysis, as well as explore the therapeutic significance of LincRNA-RoR on GBM xenografts.
Materials and Methods

Cell culture
The normal human glial cell line, HEB, was generously provided by Professor Guang-mei Yan (Department of Pharmacology, Sun Yat-sen University, Guangzhou, China). The human U87-MG, T98G and LN229 glioblastoma cell lines from ATCC was authenticated by short tandem repeat profiling (Beijing Microread Genetics, Beijing, China) and passaged for less than 6 months. Human primary GBM1 cells, primary astrocytes (sw16-N) and its matched GBM cells (sw16-T) were established and maintained in our laboratory [20, 21] . HEB, U87-MG, T98G, LN229, sw16-N, sw16-T and GBM1 cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (Gibco, Grad Island, NY), 100 μg/ml penicillin and 100 U/ml streptomycin. All the cells were incubated at 37℃ in a humidified incubator with 5% CO2.
Patients and tissue specimens
Ten fresh GBM tumor specimens and the matching non-tumor tissues were collected by surgery from Department of Neurosurgery, Southwest Hospital, Third Military Medical University (TMMU). Written informed consents were obtained from the patients or their guardians. All patients had not received radiotherapy or chemotherapy before surgery. All the experimental procedures regarding human subjects had been approved by the ethics committees of the Third Military Medical University.
Lentiviral vectors transfection procedures
The human LincRNA-RoR overexpression lentiviral vector and its negative control vector were purchased from GenePharma (Shanghai, China). Cells were infected with lentivirus in the presence of 8 μg/ml polybrene.
Glucose uptake, Lactate production and ATP Assay
QuantiChrom TM Glucose Assay Kit (DIGL-100) and EnzyChrom TM L-Lactate Assay Kit (ECLC-100) were obtained from BioAssay Systems (Hayward, CA). ATP Assay Kit (S0026) was purchased from Beyotime (Shanghai, China). Briefly, cells were plated in 12-well culture dishes, and the culture medium was replaced with FBS-free DMEM 24 hrs later. After cultured for additional 24 hrs, glucose and lactate assays were performed with culture media collected from each sample according to the manufacturer's instructions. ATP assay was conducted on the cultured cells according to the manufacturer's protocol.
Quantitative real-time polymerase chain reaction (qRT-PCR)
Real-time qRT-PCR was performed as previously described [22] . The sequences of PCR primers were listed as follow: β-actin,
Western Blot
Western blotting was conducted as previously described [22] . Commercial primary antibodies included β-actin (1:1000) (AA132, Beyotime), Glut1 
Cell proliferation assays
The cell proliferation was assessed by using Cell Counting Kit (CCK-8) (C0038, Beyotime). Briefly, cells were seeded in a 96-well plate at a density of 1.5×10 3 cells/well. CCK8 was added to each well every 24 hrs for up to 4 days. The light absorbance was then measured at a wavelength of 450 nm.
In vivo xenograft experiments
For evaluation of tumor growth in vivo, 1×10 6 U87 cells were injected subcutaneously into 5-weekold male BALB/c nude mice. Four weeks later, tumor volume was calculated by the formula V= ab 2 /2 (a: tumor length, b: tumor width). The animal experiments were approved by the Institutional Animal Care and Use Committee of Southwest Hospital, Third Military Medical University in accordance with the Guide for the Care and Use of Laboratory Animals.
HE and immunohistochemistry staining
HE and immunohistochemistry staining of xenograft tumors were performed as previously described [20] . Commercial antibodies were mouse anti-human Ki67 (Kit-0005, Maixin, Fuzhou, China), rabbit anti-human Glut1 
Statistical analysis
All experiments were performed at least in triplicates and representative data were shown. The unpaired two-group comparison and multiple comparisons were made with Student's t test or one-way ANOVA, respectively. Data were presented as the mean ± SD. P < 0.05 (*) and P < 0.01 (**) were considered statistically significant.
Results
Expression of LincRNA-RoR is reduced in human GBM tissues and GBM cells
To determine the expression of LincRNA-RoR in human GBMs, we investigated 10 cases of GBM specimens and found that LincRNA-RoR expression in tumor tissues was significantly lower than that in adjacent non-tumor tissues ( Figure 1A) . We further examined the endogenous level of LincRNA-RoR in a panel of GBM cells, including U87, T98G, LN229, primary GBM1 and sw16-T, as well as normal glial cells (human primary astrocytes sw16-N and HEB). The level of LincRNA-RoR was significantly lower in GBM cells (T98G, LN229, U87 GBM1 and sw16-T) compared to HEB and sw16-N cells ( Figure 1B) . These results indicate that the expression of LincRNA-RoR is reduced in GBM.
LincRNA-RoR inhibits the aerobic glycolysis of GBM cells
To explore the role of LincRNA-RoR in aerobic glycolysis, U87 and GBM1 cells were used to generate LincRNA-RoR-overexpression cells (Figure 2A) . We found that LincRNA-RoR overexpression significantly impeded glucose uptake ( Figure 2B ) and L-lactate production ( Figure 2C) . Accordingly, GBM cells with LincRNA-RoR-overexpression produced more ATP than control cells ( Figure 2D ). These data indicate that LincRNA-RoR inhibits aerobic glycolysis of GBM cells. 
LincRNA-RoR inhibits the expression of Rictor, p-Akt and glycolytic molecules to suppress the proliferation of GBM cells
The molecular mechanisms on the regulation of glucose metabolism by LincRNA-RoR were also investigated. mTORC2 has been reported as an important regulator of Akt activation and plays pivotal role in cancer metabolism [23, 24] . Rictor is the key component of mTORC2 [25] . Of note, mTORC2 activity is significantly elevated and exerts oncogenic function in glioma cells [26] . We thus investigated whether LincRNA-RoR could regulate mTORC2. Our results revealed that LincRNA-RoR overexpression reduced the level of Rictor and attenuated the phosphorylation of Akt (Ser473) (Figure 3A) . The important downstream molecules of Akt pathway, p-mTOR (Ser2448) and p-S6 (Ser235/236), were also decreased upon LincRNA-RoR overexpression ( Figure 3A) . Moreover, the expression of glycolytic effectors, including Glut1, HK2, PKM2 and LDHA, was remarkably decreased in LincRNA-RoR-overexpressed GBM cells in comparison with their control counterparts ( Figure 3A) . Functionally, LincRNARoR overexpression suppressed the proliferation (Figure 3B ) of GBM cells in vitro. These results indicate that LincRNA-RoR inhibits proliferation of GBM cells through Rictor/Akt pathway.
LincRNA-RoR restrains tumor growth in vivo and inhibits the expression of glycolytic molecules in GBM xenografts
Furthermore, we investigated the effect of LincRNA-RoR on tumorigenesis of GBM cells. As shown in Figure 4A , the weight and volume of the xenografts with LincRNA-RoR overexpression were dramatically reduced compared with control xenografts. Meanwhile, the percentage of Ki67 positive cells was significantly decreased in LincRNA-RoR overexpression xenografts ( Figure 4B) . Additionally, down-regulation of Glut1, HK2, PKM2, LHDA, Rictor, p-Akt (Ser473), p-mTOR (Ser2448) and p-S6 (Ser235/236) was observed in the xenografts derived from LincRNA-RoR-overexpressed cells as compared with that derived from control cells ( Figure  5A , B, C and Figure 6A, B) , demonstrating that LincRNA-RoR might inhibit tumor growth via suppressing tumor glycolysis. 
Discussion
GBM cells prefer to acquire energy from glycolysis instead of oxidative phosphorylation. Targeting glycolysis is proposed as a promising therapeutic strategy for GBM treatment [13, 27, 28] . Our results for the first time showed that LincRNA-RoR inhibited the expression of Rictor, reduced the activity of Akt, and impaired the expression of glycolytic molecules, by which the proliferation of GBM cells was restrained ( Figure 7B) . These data revealed LincRNA-RoR as a new suppressor of GBM aerobic glycolysis with therapeutic potential.
In glioma, Akt activation has been proved to be tightly correlated with tumor malignancy, including drug-resistant and tumor progression [29] [30] [31] [32] . Akt inhibitor shows anticancer and radiosensitizing effects in malignant glioma cells [33] , implying that targeting key regulators controlling Akt signaling activity might disrupt the malignant behaviors of gliomas. Previous studies have demonstrated that Akt activity is tightly regulated by mTORC2, which responds to growth factor and functions as a major activator of Akt [24] . However, the mechanisms on mTORC2 regulation in gliomas are still poorly understood.
In this study, we identified LincRNA-RoR as an important negative regulator of mTORC2-Akt signaling. The data showed that LincRNA-RoR impaired the expression of Rictor, an important component of mTORC2 complex, and thus interrupted mTORC2 function followed by inhibition of Akt activity, which functionally disrupted aerobic glycolysis in GBM cells. Our finding is in consistent with previous studies showing that upregulated Rictor expression and mTORC2 activity in glioma promotes cell growth and motility [26] , underscoring the important role of this signaling pathway in glioma progression.
Akt stimulates aerobic glycolysis in cancer cells [34] . Several glycolytic effectors, such as Glut1, HK2, PKM2 and LDHA, are aberrantly expressed in glioma, and play vital roles in tumorigenesis [5, 35] . Glut1 has been identified as one of the proteins that are up-regulated in GBM to enhance the "Warburg effect", especially in hypoxic microenvironments [36] . HK2 is the first key enzyme of glycolysis. Depletion of HK2 in GBM cells can restore oxidative glucose metabolism and increase sensitivity to cell death inducers, such as radiation and temozolomide [26] . Pyruvate kinase is an important enzyme of glycolysis by transferring the phosphoryl group of phosphoenolpyruvate (PEP) onto ADP to form ATP and pyruvate. In glioma, PKM2 expression is up-regulated in a grade-specific manner and loss of PKM2 results in cell death [37, 38] . Meanwhile, PKM2 dephosphorylation by Cdc25A promotes the "Warburg effect" and tumorigenesis [39] . LDHA catalyzes the conversion of pyruvate to lactate and is considered to be a key checkpoint of anaerobic glycolysis [3] . Our results show that LincRNA-RoR overexpression inhibits the growth of GBM xenografts with the decreased expression of Glut1, HK2, PKM2 and LDHA, suggesting that LincRNA-RoR could be used as a potential therapeutic target for GBM.
We also determined the inhibition of aerobic glycolysis in GBM cells by LincRNA-RoR through measuring glucose and L-lactate in the medium, total ATP, and a panel of glycolytic effectors in the cells, which are known parameters in the literature reflect the status of cell glycometabolism [7, 28] . However, we wished to mention that the amount of glycolysis related-metabolites and the glucose flux might provide another set of evidence to confirm the inhibitory effects of LincRNA-RoR on glycolysis.
Our results also showed that the expression of LincRNA-RoR was significantly lower in GBM tissue as compared with their adjacent non-tumor tissue. However, the expression of LincRNA-RoR exhibits heterogeneity in different type of malignancy. For example, LincRNA-RoR is up-regulated in epithelial malignant tumors, including breast cancer, hepatocellular cancer, colorectal cancer, pancreatic cancer and endometrial cancer [19] . In consideration of the critical role of LincRNA-RoR in regulating cell metabolism and other oncogenic phenotypes [19] , it should be interesting to clarify the regulatory mechanism on LincRNA-RoR expression. Zhang et al. found that NRF2 could bind to the promoter region of LincRNA-RoR to suppress the expression of LincRNA-RoR [40] . Since NRF2 had been reported to serve as an oncogenic protein in GBM [41] [42] [43] , we supposed that high expression of NRF2 might inhibit the expression of LincRNA-RoR in GBM cells, which needed to be further investigated.
Conclusion
Taken together, our study reveals a novel function of LincRNA-RoR in GBM. LincRNA-RoR is significantly down-regulated in GBM and enforced expression of LincRNA-RoR inhibits glycolysis and the growth of GBM xenografts. Therefore, LincRNA-RoR may be a promising therapeutic target towards GBM glycolysis. 
